Clinical Trial Update: Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study [Phase 2]

View source ↗

Summary

Phase 2 trial investigating topical sirolimus 2% for Epidermolysis Bullosa Simplex and related conditions has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa Simplex
• Epidermolysis Bullosa Simplex Kobner
• Weber-cockayne Syndrome

Drugs mentioned

• Topical Sirolimus 2% (sirolimus)

Snippet

Sponsor: Stanford University | Conditions: Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner | Phase 2 | Status: COMPLETED | Results posted: 2020-01-30